1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFY26 funding opportunities are announced as available but no specific application deadline was listed on the page.
Lung Cancer Research Program (LCRP) is sponsored by Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). Supports innovative research in lung cancer, including clinical and translational studies, to improve patient outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Lung Cancer Research Program, Congressionally Directed Medical Research Programs You are using an outdated browser. Please upgrade your browser to improve your experience. U.S. Department of War organization.
Due to routine system maintenance the CDMRP website will be unavailable from COB 24 April - 27 April COB.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS Transforming Health Care through Innovative and Impactful Research Vision – To eradicate deaths and suffering from lung cancer to better the health and welfare of Service Members, Veterans, and the general public Mission – Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, management, and treatment for the control and cure of » Click on image to View Summary Sheet Lung cancer is the leading cause of cancer mortality in the United States, accounting for 20% of all deaths.
1 This year, more than 234,580 U.S. men and women will be diagnosed with lung cancer, and over 125,000 will die from the disease. Lung cancer is generally diagnosed at an advanced, incurable stage because patients often lack signs and symptoms in the early stages of the disease.
Several factors have been shown to contribute to the development of lung cancer, smoking and exposure to environmental carcinogens being the most prevalent; however, 10-15% of lung cancers occur in people who are non-smokers. 2 Lung cancer risk for our military is significant, with 24% to as high as 38% of Service Members smoking compared to 14% of civliians. 3 Deployments also worsen smoking rates by about 50%.
Among military Veterans, lung cancer is a leading cause of cancer-related deaths, with about 15 Veterans dying of lung cancer each day. 4 An estimated 900,000 Veterans remain at risk due to age, smoking, and other environmental exposures during and after military service.
5 Despite improved screening methods for lung cancer and advances in treatment, the 5-year survival rate remains low at 27% for non-small cell lung cancer and only 7% for small cell lung cancer. 1 The LCRP has developed a strategy to address multiple issues in lung cancer research over the cancer continuum of care spectrum.
The following Areas of Emphasis are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will lead to reduced suffering from lung cancer and improved quality of life for Service Members, Veterans, and the general public. Understand the molecular mechanisms of initiation and progression to lung cancer. Understand contributors to lung cancer development other than tobacco.
Understand the biology of metastatic/oligometastatic disease progression. Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries. Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
Detection, Diagnosis, and Surveillance Improve and expand approaches to screening and early detection of lung cancer. Identify strategies for prompt detection and/or characterization of progressive disease. Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
Develop or optimize biomarkers to assist with therapeutic decision-making. Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.
Health Outcomes and Survivorship Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on patients, families, and support systems with respect to the impact on quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects. Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer.
Reduce differences among high-risk groups and populations with limited access to optimal clinical care and resources 1 https://seer. cancer. gov/statfacts/html/common.
html . 2 https://www. cancer.
org/cancer/latest-news/why-lung-cancer-strikes-nonsmokers. html 3 US Secretary of Defense. 2016.
Memorandum for Secretaries of the Military Departments. Washington, DC: US Secretary 4 https://www. research.
va. gov/programs/pop/lpop. cfm .
5 Moghanaki, D and Hagan M. 2020. Strategic Initiatives for Veterans with Lung Cancer.
Federal Practitioner , S76.
Congressional Appropriations Recent Applications Recommended for Funding FY24 Peer Review Participants LCRP-Supported Key Research Resources Detection of Early Lung Cancer among Military Personnel (DECAMP) Lung Cancer Biospecimen Resource Network (LCBRN) Boston University Medical Campus Detection of Early Lung Cancer Among Military Personnel (DECAMP) [Click on image to watch on DVIDS] CDMRP Advances AI-Based Metastatic Cancer Detection Through VA Partnerships Lung Cancer Research Program Booklet FY24 LCRP Recommended for Funding List THE CDMRP FUNDS RESEARCH TO ENHANCE TREATMENT AND UNDERSTANDING OF BRAIN METASTASES IN LUNG CANCER CAR T-cell Therapy for Lung Cancer – Incorporation of Self-Amplification and Safety Mechanisms Yovana Portillo - Accidentally Cancer Free Innovative Drug Combinations to Improve Immunotherapy for the Treatment of Non-Small Cell Lung Cancer Colleen Conner Ziegler - Being Part of the Solution in Hopes to Beat the Odds Cheryl Vial: Finding hope in Advancing Lung Cancer Research FY15 LCRP Recommended for Funding List Jim Pantelas: A New Perspective Leads to a Passion for Life and Advocacy Genetic Implications and Novel Targets for the Treatment of Non-Small Cell Lung Cancer Study explores driver behind lung cancer tumor progression (external link) A Consumer's Perspective: Linnea Duff LCRP Previous Highlights… Click here to provide feedback/comments to the LCRP Last updated Wednesday, May 13, 2026
According to the current listing, eligibility includes: Eligibility criteria not explicitly stated on the program overview page; applicants should review individual funding opportunity announcements. Confirm the full requirements in the official notice before applying.
The current listing shows $20 million total for FY26. Verify award ceilings, matching requirements, and allowable costs in the official notice.
This listing does not include a published deadline, but it is an annual program. Check the official notice for the current cycle's exact dates.
Lung Cancer Research Program (LCRP) is funded by Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article